文献速递消化道肿瘤与早癌

SOX9介导的增强子驱动干细胞样程序阻断结直肠癌肠分化

An Enhancer-Driven Stem Cell-Like Program Mediated by SOX9 Blocks Intestinal Differentiation in Colorectal Cancer.
PubMed 文献 · Gastroenterology · 2021-09-25

该研究旨在阐明阻断肠道分化的关键因子及其转录与表观遗传程序,为结直肠癌治疗提供临床前证据。研究发现SOX9在结直肠癌中异位高表达,通过结合全基因组增强子直接激活Paneth细胞和干细胞相关基因(包括PROM1),形成PROM1-SOX9正反馈环路,破坏SOX9活性可诱导肠道分化并抑制原发肿瘤生长。

要点

  • SOX9在结直肠腺瘤和腺癌中异位高表达,促进干细胞样程序并阻断肠分化。
  • SOX9结合全基因组增强子直接激活PROM1等干细胞相关基因,形成正反馈环路。
  • 破坏SOX9活性可诱导肠道分化并抑制原发结直肠癌肿瘤生长。

核心结论

  • SOX9是增强子驱动干细胞样程序的核心调控因子,阻断肠道分化,为克服结直肠癌分化缺陷的治疗开发提供依据。

研究设计与样本

  • 分析转基因小鼠和患者的肠道组织,采用组织病理学和免疫染色。
  • 对人结直肠癌细胞和鼠肿瘤类器官进行遗传操作以开展功能研究。
  • 通过RNA测序获取基因表达谱,利用染色质免疫沉淀测序确定组蛋白修饰和转录因子结合。

主要发现

  • 小鼠模型和患者的肠道腺瘤及结直肠腺癌显示SOX9异位且表达升高。
  • 功能实验表明人结直肠癌细胞系和工程化肿瘤类器官需要SOX9。
  • 破坏SOX9活性通过诱导肠道分化损害原发结直肠癌肿瘤生长。
  • SOX9通过结合全基因组增强子直接激活Paneth和干细胞活性相关基因,包括PROM1。
  • SOX9通过Wnt响应性内含子增强子上调PROM1,PROM1利用其第一个胞内结构域支持干细胞信号,至少部分通过SOX9,强化PROM1-SOX9正反馈环路。

临床怎么用

  • SOX9及其增强子驱动的干细胞样程序可作为结直肠癌治疗的潜在靶点。
  • 靶向SOX9活性可能通过诱导肠道分化抑制肿瘤生长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Genomic alterations that encourage stem cell activity and hinder proper maturation are central to the development of colorectal cancer (CRC). Key molecular mediators that promote these malignant properties require further elucidation to galvanize translational advances. We therefore aimed to characterize a key factor that blocks intestinal differentiation, define its transcriptional and epigenetic program, and provide preclinical evidence for therapeutic targeting in CRC. METHODS: Intestinal tissue from transgenic mice and patients were analyzed by means of histopathology and immunostaining. Human CRC cells and neoplastic murine organoids were genetically manipulated for functional studies. Gene expression profiling was obtained through RNA sequencing. Histone modifications and transcription factor binding were determined with the use of chromatin immunoprecipitation sequencing. RESULTS: We demonstrate that SRY-box transcription factor 9 (SOX9) promotes CRC by activating a stem cell-like program that hinders intestinal differentiation. Intestinal adenomas and colorectal adenocarcinomas from mouse models and patients demonstrate ectopic and elevated expression of SOX9. Functional experiments indicate a requirement for SOX9 in human CRC cell lines and engineered neoplastic organoids. Disrupting SOX9 activity impairs primary CRC tumor growth by inducing intestinal differentiation. By binding to genome wide enhancers, SOX9 directly activates genes associated with Paneth and stem cell activity, including prominin 1 (PROM1). SOX9 up-regulates PROM1 via a Wnt-responsive intronic enhancer. A pentaspan transmembrane protein, PROM1 uses its first intracellular domain to support stem cell signaling, at least in part through SOX9, reinforcing a PROM1-SOX9 positive feedback loop. CONCLUSIONS: These studies establish SOX9 as a central regulator of an enhancer-driven stem cell-like program and carry important implications for developing therapeutics directed at overcoming differentiation defects in CRC.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Liang X, Duronio GN, Yang Y, et al. An Enhancer-Driven Stem Cell-Like Program Mediated by SOX9 Blocks Intestinal Differentiation in Colorectal Cancer. Gastroenterology. 2021. PMID: 34571027. doi:10.1053/j.gastro.2021.09.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。